Whitehawk Therapeutics Announces Key Participation in Major Upcoming Investor Conferences

Whitehawk Therapeutics Set for Major Investor Engagements

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an innovative leader in the field of oncology therapeutics, is gearing up for two crucial investor conferences scheduled to take place in New York City this September. The company's President and CEO, Dr. Dave Lennon, will host a fireside chat at both events, showcasing Whitehawk’s commitment to advancing cancer treatment technologies.

The first event, the Morgan Stanley 23rd Annual Global Healthcare Conference, will be held on September 8, 2025. Dr. Lennon’s talk is slated for 4:50 PM ET, where he is expected to discuss the company’s focus on employing cutting-edge technologies to enhance established tumor biology methodologies, particularly in the realm of antibody-drug conjugate (ADC) cancer therapies.

Following closely, the H.C. Wainwright 27th Annual Global Investment Conference will take place on September 9, 2025, and Dr. Lennon will present at 3:30 PM ET. This conference will provide an additional platform for him to share insights into Whitehawk’s pioneering approaches and their implications for the future of cancer treatment.

Whitehawk Therapeutics is distinguished for its advanced work in developing ADC therapies, which are engineered to address the limitations of prior generations. The company’s three-asset ADC portfolio is not only innovative but also positioned to make a substantial difference for patients who face difficult-to-treat cancers. These therapeutic candidates are part of an exclusive global development and commercialization agreement with WuXi Biologics, amplifying the potential for impactful treatment options in oncology.

Live Webcast Availability

For those unable to attend in person, Whitehawk Therapeutics will facilitate live webcasts of these engagements, accessible through the Whitehawk Therapeutics investor relations website. Following the live discussions, replays will be available for approximately 30 days, ensuring a broad audience can access valuable insights and information about the company’s progress and future directions.

About Whitehawk Therapeutics

Founded with the mission to push the boundaries of cancer treatment, Whitehawk Therapeutics leverages advanced technologies in tumor biology to deliver improved ADC therapies. By actively focusing on innovation and research, the company aims to provide significant breakthroughs in oncology care, ultimately enhancing patient outcomes.

Interested parties can learn more about Whitehawk Therapeutics by visiting their official website at www.whitehawktx.com or by engaging with the company on LinkedIn, where updates and insights into their advancements are frequently shared. As Whitehawk prepares for these significant conferences, the anticipation among investors and the medical community alike continues to grow.

In conclusion, the participation of Whitehawk Therapeutics in these prestigious conferences marks a pivotal moment in its growth trajectory, emphasizing its role as a significant player in the oncology therapeutics space and its commitment to transforming cancer treatment for patients around the globe.